Discussed and informed on the Biocom CA 2026 Life Science Economic Impact Report Advocated against policies that would undermine economic development in the life sciences (i.e., MFN, MDPNP)
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions